Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acadia Pharmaceutica (NQ: ACAD )

15.63 -0.08 (-0.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acadia Pharmaceutica

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
Acadia led a biotech selloff on Wednesday as Daybue sales missed expectations. 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Expert Outlook: ACADIA Pharmaceuticals Through The Eyes Of 5 Analysts
Via Benzinga
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
A Closer Look at 13 Analyst Recommendations For ACADIA Pharmaceuticals
Via Benzinga
Expert Ratings For ACADIA Pharmaceuticals
Via Benzinga
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
From Acadia Pharmaceuticals Inc.
Via Business Wire
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
From Acadia Pharmaceuticals Inc.
Via Business Wire
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals
Via Benzinga
Expert Ratings For ACADIA Pharmaceuticals
Via Benzinga
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
From Acadia Pharmaceuticals, Inc.
Via Business Wire
3 Sorry Pharma Stocks to Sell in May While You Still Can
Discover three pharma stocks to sell in May while you still can. Avoid these companies facing significant setbacks. 
Via InvestorPlace
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications. 
Via Benzinga
Topics Data Breach
Exposures Information Security
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Shhh! 3 Secret Penny Stocks Flying Below Wall Street’s Radar
Under-the-radar penny stocks can be some of the most rewarding investments on the market. Here are three to consider. 
Via InvestorPlace
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACAD Stock Earnings: ACADIA Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
ACAD stock results show that ACADIA Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)
Via Benzinga
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
From Acadia Pharmaceuticals Inc.
Via Business Wire
3 Pharma Stocks to Sell in April Before They Crash & Burn
Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside. 
Via InvestorPlace
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.